Search our Database of Scientific Publications and Authors

I’m looking for a

    820 results match your criteria Asia-Pacific Journal of Clinical Oncology [Journal]

    1 OF 17

    Uterine adenosarcoma in Japan: Clinicopathologic features, diagnosis and management.
    Asia Pac J Clin Oncol 2018 Feb 14. Epub 2018 Feb 14.
    Department of Gynecology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
    Aim: Uterine adenosarcoma is a rare malignancy with limited cohort data in Asian countries. This study evaluated the clinicopathologic features of Japanese patients with uterine adenosarcoma and their potential treatment challenges.

    Methods: A retrospective chart review was performed at the National Cancer Center Hospital, Japan from 2000 to 2016. Read More

    Investigation of estimated glomerular filtration rate and its perioperative change in patients with upper urinary tract urothelial carcinoma: A multi-institutional retrospective study.
    Asia Pac J Clin Oncol 2018 Feb 12. Epub 2018 Feb 12.
    Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan.
    Aim: To investigate the association of perioperative estimated glomerular filtration rate (eGFR) with prognosis in patients with upper urinary tract urothoelial caicinoma (UTUC).

    Methods: A total of 433 patients underwent radical nephroureterectomy with excision of the bladder cuff (RNU) at six hospitals affiliated with Kitasato University in Japan. Patients were divided into three groups each in terms of preoperative eGFR: normal eGFR (>60 mL/min/1. Read More

    Efficacy and safety of sunitinib alternate day regimen in patients with metastatic renal cell carcinoma in Japan: Comparison with standard 4/2 schedule.
    Asia Pac J Clin Oncol 2018 Jan 31. Epub 2018 Jan 31.
    Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
    Aim: Sunitinib is a standard agent for metastatic renal cell carcinoma (mRCC). The standard schedule, 4 weeks-on followed by 2 weeks-off (4/2 schedule), often does not maintain an adequate dosage because of the severe adverse events (AEs). We compared the efficacy and safety of an alternative every other day (q. Read More

    FLT3-ITD positive acute myeloid leukemia: A retrospective analysis of the role of allogeneic transplant and allelic ratio in patient management.
    Asia Pac J Clin Oncol 2018 Jan 31. Epub 2018 Jan 31.
    Cancer Care Services, Royal Brisbane and women's Hospital, Brisbane, Australia.
    Aim: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) positive AML is associated with increased relapse risk and reduced overall survival (OS) compared to non-FLT3-mutated AML. The aim of this study was to evaluate the impact of allelic ratio and allogeneic transplant on outcomes in FLT3-ITD+ AML.

    Methods: A retrospective study across five centers in Queensland, Australia, was conducted to examine survival outcomes and impact of FLT3-ITD allelic ratio and allograft. Read More

    Patterns of care of superficial soft tissue sarcomas: it is not always just a lump.
    Asia Pac J Clin Oncol 2018 Jan 31. Epub 2018 Jan 31.
    Prince of Wales Hospital Clinical School, Faculty of Medicine, University of New South Wales, Australia.
    Aim: Superficial soft tissue sarcomas (S-STS) are generally considered low-risk tumors and have an excellent prognosis when treated with appropriate surgery and adjuvant therapy. However, they are often misdiagnosed then mistreated, leading to significant morbidity. This study aims to examine the patterns of care and outcomes of patients with S-STS, comparing those initially managed through sarcoma units versus elsewhere. Read More

    Serum-based six-miRNA signature as a potential marker for EC diagnosis: Comparison with TCGA miRNAseq dataset and identification of miRNA-mRNA target pairs by integrated analysis of TCGA miRNAseq and RNAseq datasets.
    Asia Pac J Clin Oncol 2018 Jan 30. Epub 2018 Jan 30.
    University School of Biotechnology, Guru Gobind Singh Indraprastha University, Dwarka, New Delhi, India.
    Aim: To evaluate the diagnostic potential of a six microRNAs (miRNAs) panel consisting of miR-21, miR-144, miR-107, miR-342, miR-93 and miR-152 for esophageal cancer (EC) detection.

    Methods: The expression of miRNAs was analyzed in EC sera samples using quantitative real-time PCR. Risk score analysis was performed and linear regression models were then fitted to generate the six-miRNA panel. Read More

    Efficacy of management strategies for aromatase inhibitor-induced arthralgia in breast cancer patients: a systematic review.
    Asia Pac J Clin Oncol 2018 Jan 30. Epub 2018 Jan 30.
    University of Sydney, Sydney Adventist Hospital, SAN Integrated Cancer Centre, Wahroonga, New South Wales, Australia.
    Aromatase inhibitors are the gold standard in the treatment of hormone receptor-positive breast cancer, but lead to an arthralgia syndrome which is implicated in 13-22% of noncompliance. This is the first systematic review of the efficacy of existing management strategies for this side effect. Eligible studies were retrieved from computer searches of Medline, Cochrane and Embase and the significant intervention groups were identified. Read More

    A mixed methods analysis of experiences and expectations among early-career medical oncologists in Australia.
    Asia Pac J Clin Oncol 2018 Jan 26. Epub 2018 Jan 26.
    Department of Medical Oncology, Royal Brisbane and Women's Hospital, Queensland, Australia.
    Aim: A viable and sustainable medical oncology profession is integral for meeting the increasing demand for quality cancer care. The aim of this study was to explore the workforce-related experiences, perceptions and career expectations of early-career medical oncologists in Australia.

    Methods: A mixed-methods design, including a survey (n  =  170) and nested qualitative semistructured interviews (n  =  14) with early-career medical oncologists. Read More

    Capecitabine/cisplatin versus 5-fluorouracil/cisplatin in Chinese patients with advanced and metastatic gastric cancer: Re-analysis of efficacy and safety data from the ML17032 phase III clinical trial.
    Asia Pac J Clin Oncol 2018 Jan 26. Epub 2018 Jan 26.
    Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangdong, China.
    Aim: To confirm non-inferiority and test potential superiority of capecitabine/cisplatin (XP) over 5-fluorouracil (5-FU)/cisplatin (FP) as first-line treatment for advanced gastric cancer (AGC) in Chinese patients.

    Methods: In open-label phase III ML17032 trial, AGC (stage IIIA-IV) patients with or without metastases were randomized 1:1 to receive cisplatin (80 mg/m/day intravenous [IV] day 1) with either capecitabine (1000 mg/m/day oral [PO] twice daily [BID], days 1-14; XP) or 5-FU (800 mg/m/day continuous IV days 1-5; FP) every 3 weeks. The primary objective was to confirm the non-inferiority of XP over FP for progression-free survival (PFS). Read More

    Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/T-CL.
    Asia Pac J Clin Oncol 2018 Jan 25. Epub 2018 Jan 25.
    Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, China.
    Aim: To better understand the T-cell immunodeficiency status in patients with peripheral T-cell lymphomas (PTCLs) and NK/T-cell lymphomas (NK/T-CLs), the T-cell inhibitory receptors expression pattern was investigated.

    Methods: The expression levels of programmed death 1 (PD-1), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), B/T lymphocyte attenuator (BTLA), lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobulin-3 (TIM-3), T-cell immunoglobulin and ITIM domain (TIGIT) genes were detected in peripheral blood mononuclear cells (PBMCs) from patients and healthy volunteers by quantitative real-time-PCR, the correlation between different gene expression levels was analyzed.

    Results: Significantly higher expression of PD-1, CTLA-4, BTLA, LAG-3, TIM-3 and TIGIT can be observed as a common characteristic in patients with PTCL or NK/T-CL. Read More

    Impact of body mass index on the oncological outcomes of patients with upper and lower urinary tract cancers treated with radical surgery: A multi-institutional retrospective study.
    Asia Pac J Clin Oncol 2018 Jan 22. Epub 2018 Jan 22.
    Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan.
    Aim: To evaluate the impact of body mass index (BMI) on the oncological outcomes of urothelial carcinoma (UC) patients.

    Patients And Methods: We retrospectively analyzed data from 818 patients with upper tract urothelial cancer (UTUC) and bladder cancer (BC) who were treated with radical nephroureterectomy (RNU) or radical cystectomy (RC) between 1990 and 2015 at six different institutions in Japan. Patients with distant metastasis at diagnosis and those who received neoadjuvant therapies were excluded, leaving 727 eligible patients (UTUC: n = 441; BC: n = 286). Read More

    Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis.
    Asia Pac J Clin Oncol 2018 Jan 19. Epub 2018 Jan 19.
    Cancer Care Centre, St George Hospital, Gray Street, Kogarah, Sydney, NSW, Australia.
    Background: We performed a meta-analysis to quantify toxic death, adverse events (AEs) and treatment discontinuation due to AEs from checkpoint inhibitors (CI).

    Methods: We searched for randomized trials with adequate reporting for toxicity outcomes. Pooled risk ratios were estimated for CI versus chemotherapy or different combinations of these agents. Read More

    High neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy.
    Asia Pac J Clin Oncol 2018 Jan 17. Epub 2018 Jan 17.
    Department of Medical Oncology, Alfred Health, Melbourne, Australia.
    Aim: To evaluate the role of neutrophil-to-lymphocyte ratio as a prognostic marker in squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy.

    Methods: A retrospective chart review was performed on patients presenting to our service between 2001 and 2014. Overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier estimates. Read More

    Cut-point for Ki-67 proliferation index as a prognostic marker for glioblastoma.
    Asia Pac J Clin Oncol 2018 Jan 16. Epub 2018 Jan 16.
    Sydney Medical School, University of Sydney, Sydney, Australia.
    Introduction: Ki-67 proliferation index (Ki-67 index) is used to quantify cell proliferation during histopathological assessment of various tumors including glioblastoma (GB).

    Aim: We aimed to assess correlation between Ki-67 index and overall survival in patients with GB and determine a cut-point for Ki-67 index that predicts for poorer survival.

    Method: Records of adult patients diagnosed with GB on histopathological specimens at a tertiary cancer center in Sydney between 1 January 2002 and 30 July 2012 were retrieved. Read More

    Complications of curative radiation treatment for early prostate cancer.
    Asia Pac J Clin Oncol 2018 Jan 16. Epub 2018 Jan 16.
    Canterbury District Health Board, Christchurch Hospital, Christchurch, New Zealand.
    Aim: To report the incidence of urological complications following curative radiation treatment for early prostate cancer, including minimally invasive urological procedures (MUIP), hospital admissions and open surgical procedures. Second malignancies following radiation are also reported and compared with patients undergoing a prostatectomy.

    Methods: Included were patients receiving curative intent external beam radiation treatment for early prostate cancer between January 1, 2002, and December 31, 2009. Read More

    MAML1 and TWIST1 co-overexpression promote invasion of head and neck squamous cell carcinoma.
    Asia Pac J Clin Oncol 2018 Jan 15. Epub 2018 Jan 15.
    Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran.
    Aims: Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide with considerable morbidity and mortality. Invasion and metastasis of HNSCC is a complex process involving multiple molecules and signaling pathways. Twist Family BHLH Transcription Factor 1 (TWIST1) and Mastermind-like 1 (MAML1) are essential in induction of epithelial-mesenchymal transition through direct regulation of implicated molecules in cellular adhesion, migration and invasion. Read More

    Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer.
    Asia Pac J Clin Oncol 2018 Jan 10. Epub 2018 Jan 10.
    Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
    Aim: We describe a subgroup analysis assessing the efficacy and safety of ramucirumab monotherapy in East Asian (EA) patients from the REGARD trial.

    Methods: Patients with advanced gastric or gastroesophageal junction adenocarcinoma with progressive disease were randomized 2:1 to receive ramucirumab (8 mg/kg) plus best supportive care (BSC) or placebo plus BSC every 2 weeks. Post hoc subset analyses were performed on the EA and non-EA intention-to-treat populations. Read More

    Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.
    Asia Pac J Clin Oncol 2018 Jan 10. Epub 2018 Jan 10.
    Olivia Newton-John Cancer Wellness and Research Center, Austin Hospital, Heidelberg, Victoria, Australia.
    Background: Docetaxel is an effective therapy for metastatic castration-resistant prostate cancer (mCRPC); however, many patients experience febrile neutropenia (FN) and cease treatment early due to toxicity. It is not known whether lower dose (LD) q3-weekly docetaxel impacts toxicity or efficacy.

    Methods: Multicenter retrospective study included 166 patients with mCRPC who received q3-weekly docetaxel between 2010 and 2015. Read More

    Estimating radiotherapy demands in South East Asia countries in 2025 and 2035 using evidence-based optimal radiotherapy fractions.
    Asia Pac J Clin Oncol 2018 Jan 8. Epub 2018 Jan 8.
    Faculty of Health Sciences, National University of Malaysia, Kuala Lumpur, Malaysia.
    Background And Purpose: As about 50% of cancer patients may require radiotherapy, the demand of radiotherapy as the main treatment to treat cancer is likely to rise due to rising cancer incidence. This study aims to quantify the radiotherapy demand in countries in Southeast Asia (SEA) in 2025 and 2035 using evidence-based optimal radiotherapy fractions.

    Materials And Methods: SEA country-specific cancer incidence by tumor site for 2015, 2025 and 2035 was extracted from the GLOBOCAN database. Read More

    Immunomodulation characteristics by thermal ablation therapy in cancer patients.
    Asia Pac J Clin Oncol 2018 Jan 8. Epub 2018 Jan 8.
    Cancer Therapy Center, Affiliated Hospital of the Academy of Military Medical Sciences, Beijing, China.
    Aim: Thermal ablation therapy has recently emerged as a promising noninvasive treatment modality for localized solid malignancies. Except its direct tumor-cell-killing effect on local tumor tissues, the immunomodulatory effect has also long been noticed which too has substantial effect on clinical outcome, but it is complicated. Though much has been investigated and rich evidences have been achieved, the fundamental state and profile of immunomodulation by thermal ablation in cancer patients, its exact mechanism, especially the systematic mechanism, and its effect on antitumor immunity remain unclear. Read More

    Carboplatin plus pemetrexed for the elderly incurable chemo-naive nonsquamous non-small cell lung cancer: Meta-analysis.
    Asia Pac J Clin Oncol 2018 Jan 8. Epub 2018 Jan 8.
    Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
    Aim: In some developed countries, a proportion of nonsquamous non-small cell lung cancer (NSq NSCLC) patients are aged over 70 years when they are diagnosed. However, evidence of lung cancer chemotherapy usually comes from randomized controlled trials that only recruit younger patients with good performance status. In daily practice, less-toxic carboplatin + pemetrexed regimen is often used for elderly patients, although this regimen is not sufficiently supported by rigid evidence for elderly cases. Read More

    Resveratrol induced apoptosis in human gastric carcinoma SGC-7901 cells via activation of mitochondrial pathway.
    Asia Pac J Clin Oncol 2018 Jan 8. Epub 2018 Jan 8.
    Department of Molecular Biology, Jiangsu Institute of Cancer Research, Nanjing, China.
    Background: Resveratrol is a natural polyphenolic compound and its anticancer effect has been receiving considerable attention. Previous studies showed that resveratrol could inhibited the growth of human gastric carcinoma cells and apoptosis induction was an important mechanism. However, whether mitochondrial pathway was involved in resveratrol-induced apoptosis in human gastric cancer was not very clear. Read More

    Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study.
    Asia Pac J Clin Oncol 2017 Dec 28. Epub 2017 Dec 28.
    Celgene Corporation, Summit, NJ, USA.
    Background: Azacitidine safety and efficacy were established in studies of mainly Caucasian patients. Differences in drug metabolism enzymes between Caucasian and East Asian populations prevent extrapolation of drug effects between these groups. This phase 2 study evaluated azacitidine safety, efficacy and pharmacokinetics in patients with higher-risk myelodysplastic syndromes (HR-MDS) in mainland China. Read More

    Efficacy and safety of oxycodone/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea.
    Asia Pac J Clin Oncol 2017 Dec 27. Epub 2017 Dec 27.
    Division of Medical Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
    Aims: To investigate the efficacy and safety of oxycodone/naloxone in patients with chemotherapy-induced peripheral neuropathy (CIPN) inadequately controlled with pregabalin or gabapentin.

    Methods: This 4-week, multicenter, interventional, single-arm phase IV study included 72 Korean patients with CIPN inadequately controlled with pregabalin or gabapentin (Numeric Rating Scale 0-10; NRS ≥4 at baseline). In addition to pregabalin or gabapentin at existing doses, patients received 20/10 mg/day oxycodone/naloxone (up-titrated to 80/40 mg/day as needed). Read More

    Clinical response to apatinib monotherapy in advanced non-small cell lung cancer.
    Asia Pac J Clin Oncol 2017 Dec 15. Epub 2017 Dec 15.
    Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
    Aim: Apatinib, an oral tyrosine kinase inhibitor mainly targeting VEGFR-2, exerts both antiangiogenesis and antiproliferation effects. Apatinib shows clinical benefit in advanced non-small cell lung cancer (NSCLC) at an initial dose of 750 mg qd. We further assessed the efficacy and safety of apatinib at a more frequently used dose of 500 mg qd. Read More

    Prognostic significance of interimF-fluorodeoxyglucose positron emission tomography-computed tomography volumetric parameters in metastatic or recurrent gastric cancer.
    Asia Pac J Clin Oncol 2017 Dec 10. Epub 2017 Dec 10.
    Division of Oncology/Hematology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
    Aim: To evaluate the prognostic role of interim analysis of 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) volumetric parameters in patients with recurrent or metastatic advanced gastric cancer (AGC) treated with fluoropyrimidine-based palliative chemotherapy.

    Methods: Forty-four patients who underwent baseline and interim PET/CT scanning during palliative chemotherapy were analyzed retrospectively. Initial and change of metabolic parameters (MP) - metabolic tumor volume (MTV), tumor lesion glycolysis (TLG) and maximum and mean standardized uptake values (SUV) were measured with PET/CT. Read More

    Visibility of an iron-containing fiducial marker in magnetic resonance imaging for high-precision external beam prostate radiotherapy.
    Asia Pac J Clin Oncol 2017 Nov 29. Epub 2017 Nov 29.
    Department of Radiology, Gifu University School of Medicine, Gifu City, Gifu, Japan.
    Introduction: Visualization of fiducial gold markers is critical for registration on computed tomography (CT) and magnetic resonance imaging (MRI) for imaging-guided radiotherapy. Although larger markers provide better visualization on MRI, they tend to generate artifacts on CT. MRI is strongly influenced by the presence of metals, such as iron, in the body. Read More

    Initial experience of sleeve lobectomy under complete video-assisted thoracic surgery.
    Asia Pac J Clin Oncol 2018 Feb 29;14(1):114-119. Epub 2017 Nov 29.
    Department of Thoracic Surgery, Peking University Third Hospital, Beijing, China.
    Purpose: Review the initial results of a single-center complete video-assisted thoracoscopic surgery (VATS) sleeve lobectomy and discuss the key procedure of this operation, in addition to its safety and feasibility.

    Methods: Retrospectively analyze the perioperative data of 11 patients who accepted complete VATS sleeve lobectomy between May 2013 and Jun 2017 in Peking University Third Hospital, try to evaluate the safety of this procedure. All the patients were followed up and their oncological recurrence and metastasis were observed, and feasibility of VATS sleeve lobectomy for lung cancer was evaluated. Read More

    Outcomes of Asian patients with localized prostate cancer treated with combined intensity modulated radiation therapy (IMRT) and high dose rate (HDR) brachytherapy: A single institution experience.
    Asia Pac J Clin Oncol 2017 Nov 23. Epub 2017 Nov 23.
    Department of Radiation Oncology, National Cancer Institute, National University Hospital, National University Health Systems, Singapore, Singapore.
    Aim: External beam radiotherapy (EBRT) followed by high dose rate (HDR) brachytherapy boost has demonstrated minimal toxicities and improved disease control rate compared with EBRT alone in observational and randomized studies with predominantly Caucasian patients. This study aims to report the outcomes of patients treated with this approach in our predominantly Asian population.

    Methods: Medical records for patients with localized prostate cancer who received combined EBRT delivered via intensity modulated radiotherapy (IMRT) technique followed by HDR brachytherapy boost were retrospectively reviewed. Read More

    Influence of socioeconomic factors and distance to radiotherapy on breast-conserving surgery rates for early breast cancer in regional Australia; implications of change.
    Asia Pac J Clin Oncol 2017 Nov 21. Epub 2017 Nov 21.
    School of Medicine, Deakin University, Deakin Rural Health, Warrnambool, Victoria, Australia.
    Aims: Breast conserving surgery rates are affected by many factors including distance to radiotherapy and tumor-related features. Numerous studies have found women who must travel further for radiotherapy are more likely to choose mastectomy and avoid radiotherapy. We examined relationships between socioeconomic group, distance to radiotherapy services and mastectomy rates across a range of rural and metropolitan settings. Read More

    Combined transcatheter arterial chemoembolization and radiofrequency ablation in single-session for solitary hepatocellular carcinoma larger than 7 cm.
    Asia Pac J Clin Oncol 2017 Nov 10. Epub 2017 Nov 10.
    Department of Interventional Radiology, Chinese PLA General Hospital, Beijing, China.
    Aims: To evaluate technical feasibility and treatment results of combined transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) in single-session for solitary hepatocellular carcinoma (HCC) larger than 7 cm in diameter.

    Methods: Institutional review board approved this retrospective study. Written informed consent was obtained from all patients. Read More

    CBX3/heterochromatin protein 1 gamma is significantly upregulated in patients with non-small cell lung cancer.
    Asia Pac J Clin Oncol 2017 Nov 10. Epub 2017 Nov 10.
    School of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China.
    Aim: Lung cancer is typically categorized into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC comprises of the majority of lung cancer with a poor prognosis in advanced cases. Transcriptional profiling studies, including microarrays and RNA-sequencing studies, have significantly enriched our knowledge of gene expression patterns in NSCLC. Read More

    Pathological outcomes in rectal cancer following laparoscopic surgery.
    Asia Pac J Clin Oncol 2017 Nov 8. Epub 2017 Nov 8.
    Department of Colorectal Surgery, Concord Repatriation General Hospital, Sydney, NSW, Australia.
    Aim: This study examined pathological quality-of-surgery indicators in laparoscopic and open rectal cancer resection specimens.

    Methods: Retrospective analysis of consecutive, prospectively recorded laparoscopic (LR) or open (OR) resections for rectal cancer. Indicators included integrity of the perirectal fascial envelope, circumferential margin clearance, lymph node yield and distal margin clearance. Read More

    MicroRNA profiles in neuroblastoma: Differences in risk and histology groups.
    Asia Pac J Clin Oncol 2017 Nov 8. Epub 2017 Nov 8.
    Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University, İzmir, Turkey.
    Aim: To determine the miRNA expression profiles of neuroblastomas with different clinical and histological characteristics.

    Methods: In this study 24 samples from 17 patients, paraffin blocks were used. Their microRNA profiles were compared by five different analysis: analysis I: well-poorly differentiated, analysis II: before-after chemotherapy, analysis III: favorable-unfavorable histology, analysis IV: neuroblastoma-ganglioneuroma, analysis V: low-risk-middle-risk-high risk groups. Read More

    Molecular targets for the therapy of cancer associated with metabolic syndrome (transcription and growth factors).
    Asia Pac J Clin Oncol 2017 Nov 8. Epub 2017 Nov 8.
    Siberian State Medical University, Тоmsk, Russian Federation.
    Metabolic syndrome (MS) is one of the leading risk factors for the development of cardiovascular diseases, type II diabetes mellitus and reproductive system diseases. Currently, not only cardiovascular disease and reproductive history risks related with MS are frequently discussed, but it has been also shown that MS is associated with increased risk of some common cancers (endometrial cancer, postmenopausal breast cancer, colorectal cancer, biliary tract cancers and liver cancer for men). Further studies are required to understand the mechanisms of the involvement of MS components in the pathogenesis of malignant neoplasms. Read More

    Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial.
    Asia Pac J Clin Oncol 2017 Nov 8. Epub 2017 Nov 8.
    Royal Melbourne Hospital, Melbourne, Victoria, Australia.
    Aim: Assessment of magnetic resonance imaging (MRI) in glioblastoma can be challenging. For patients with recurrent glioblastoma managed on the CABARET trial, we compared disease status assessed at hospitals and subsequent blinded central expert radiological review.

    Methods: MRI results and clinical status at specified time points were used for site and central assessment of disease status. Read More

    Attitudes of patients with metastatic cancer towards research biopsies.
    Asia Pac J Clin Oncol 2017 Nov 6. Epub 2017 Nov 6.
    University of New South Wales, Kensington, NSW, Australia.
    Aim: To evaluate the attitudes of patients with different cancers towards research biopsies outside a clinical trial.

    Methods: Patients with metastatic cancer completed a questionnaire that assessed patients' willingness to consider research biopsies. Research biopsies were divided into two groups: biopsies performed as stand-alone procedures (research purposes only biopsy, RPOB) or performed during a clinically indicated biopsy (additional pass biopsy, APB). Read More

    Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey.
    Asia Pac J Clin Oncol 2017 Nov 6. Epub 2017 Nov 6.
    Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, Australia.
    Aim: Despite the considerable impact of neuroendocrine tumors (NETs) on patients' lives, the patient journey is not well documented. The aim of this survey was to identify the impact and burden of NETs from the patient perspective.

    Methods: This was a self-reported global survey regarding NET knowledge/awareness, disease impact/management, interaction with medical teams, and desired improvements. Read More

    PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
    Asia Pac J Clin Oncol 2018 Feb 3;14(1):69-73. Epub 2017 Nov 3.
    Department of Medical Oncology, The Canberra Hospital, Garran, ACT, Australia.
    Aim: There is currently a need to identify prognostic biomarkers to assist in a risk adopted approach in treatment of malignant pleural mesothelioma (MPM). Expression of programmed death ligand 1 (PD-L1) has been studied as a prognostic biomarker in a number of tumors given its central role in antitumoral immune response evasion. Four previously published analyses found PD-L1 positivity to be an adverse survival prognostic factor in MPM. Read More

    Predictors of care for patients with cancer of unknown primary site in three Australian hospitals.
    Asia Pac J Clin Oncol 2017 Nov 3. Epub 2017 Nov 3.
    Cancer Epidemiology Research Unit, Centre for Big Data Research in Health, University of New South Wales, Sydney, Australia.
    Aim: Cancer of unknown primary site (CUP) is a medically challenging malignancy with a poor prognosis. We describe an incident tertiary CUP patient cohort and identify factors predictive of specific types of health care.

    Methods: We reviewed the medical records of 217 patients diagnosed with CUP (2006-2011) in three public hospitals in New South Wales, Australia. Read More

    Lower trial participation by culturally and linguistically diverse (CALD) cancer patients is largely due to language barriers.
    Asia Pac J Clin Oncol 2018 Feb 30;14(1):52-60. Epub 2017 Oct 30.
    Centre for Oncology Education and Research Translation (CONCERT), Ingham Institute for Applied Medical Research & University of New South Wales, Liverpool, NSW, Australia.
    Aim: Clinical trials play a critical role in advancing cancer care, but international research shows that few cancer patients, particularly culturally and linguistically diverse (CALD) patients, participate in trials. This limits generalizability of trial results and increases health disparities. This study aimed to establish rates and correlates of trial participation among CALD patients in South Western Sydney Local Health District (SWSLHD), a highly culturally diverse area. Read More

    Precision oncology using a clinician-directed, tailored approach to molecular profiling.
    Asia Pac J Clin Oncol 2018 Feb 30;14(1):84-90. Epub 2017 Oct 30.
    Department of Medical Oncology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
    Aim: Precision oncology involves molecularly matching patients to targeted agents usually in early drug development (EDD) programs. Molecular profiling (MP) identifies actionable targets. Comprehensive commercial MP platforms are costly and in resource limited environments, a more practical approach to MP is necessary to support EDD and precision oncology. Read More

    1 OF 17